Vanguard Group
PHAT icon

Vanguard Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Vanguard Group’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$52.7M Sell
3,177,211
-38,361
-1% -$548K ﹤0.01% 2137
2025
Q3 		$37.8M Buy
3,215,572
+428,261
+15% +$4.42M ﹤0.01% 2288
2025
Q2 		$26.7M Buy
2,787,311
+8,624
+0.3% +$47.7K ﹤0.01% 2420
2025
Q1 		$17.4M Sell
2,778,687
-874
-0% -$5.31K ﹤0.01% 2566
2024
Q4 		$22.6M Buy
2,779,561
+83,238
+3% +$1.03M ﹤0.01% 2530
2024
Q3 		$48.7M Buy
2,696,323
+484,568
+22% +$6.77M ﹤0.01% 2189
2024
Q2 		$22.8M Buy
2,211,755
+232,642
+12% +$2.4M ﹤0.01% 2506
2024
Q1 		$21M Buy
1,979,113
+22,684
+1% +$193K ﹤0.01% 2571
2023
Q4 		$17.9M Buy
1,956,429
+33,767
+2% +$291K ﹤0.01% 2647
2023
Q3 		$19.9M Buy
1,922,662
+180,325
+10% +$2.47M ﹤0.01% 2554
2023
Q2 		$25M Buy
1,742,337
+564,840
+48% +$6.51M ﹤0.01% 2501
2023
Q1 		$8.41M Buy
1,177,497
+100,892
+9% +$886K ﹤0.01% 3032
2022
Q4 		$12.1M Buy
1,076,605
+106,851
+11% +$1.1M ﹤0.01% 2870
2022
Q3 		$10.7M Sell
969,754
-915,098
-49% -$8.72M ﹤0.01% 2930
2022
Q2 		$15.9M Sell
1,884,852
-57,849
-3% -$595K ﹤0.01% 2759
2022
Q1 		$26.4M Buy
1,942,701
+14,857
+0.8% +$240K ﹤0.01% 2625
2021
Q4 		$37.9M Buy
1,927,844
+114,193
+6% +$2.69M ﹤0.01% 2503
2021
Q3 		$58.2M Buy
1,813,651
+254,362
+16% +$8.45M ﹤0.01% 2282
2021
Q2 		$52.8M Buy
1,559,289
+79,697
+5% +$2.85M ﹤0.01% 2345
2021
Q1 		$55.6M Buy
1,479,592
+38,655
+3% +$1.62M ﹤0.01% 2256
2020
Q4 		$47.9M Buy
1,440,937
+698,588
+94% +$28.3M ﹤0.01% 2224
2020
Q3 		$27.2M Buy
742,349
+43,230
+6% +$1.5M ﹤0.01% 2308
2020
Q2 		$23M Buy
699,119
+493,607
+240% +$19M ﹤0.01% 2355
2020
Q1 		$5.31M Sell
205,512
-483
-0.2% -$16.1K ﹤0.01% 2950
2019
Q4 		$6.42M Buy
+205,995
New +$5.18M ﹤0.01% 3079

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

Vanguard Group's PHAT Position: Q4 2025 in Review

Vanguard Group reduced its Phathom Pharmaceuticals (PHAT) stake by 1.2% in Q4 2025, selling an estimated $548K and leaving 3,177,211 shares worth $52.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2137.

Vanguard Group first reported a position in PHAT in Q4 2019 and has held it in 25 quarters since. The position peaked at $58.2M in Q3 2021. 172 funds tracked by Wall St. Rank hold PHAT as of Q4 2025.

  • Vanguard Group held 3,177,211 shares of Phathom Pharmaceuticals worth $52.7M as of Q4 2025.
  • Vanguard Group sold 38,361 Phathom Pharmaceuticals shares in Q4 2025, an estimated $548K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2137 holding.
  • Vanguard Group first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 25 quarters since.
  • Vanguard Group's Phathom Pharmaceuticals position peaked at $58.2M in Q3 2021.
  • 172 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.